静脉铁剂应用中国专家共识(2019年版)

2019-05-30 中华医学会血液学分会红细胞疾病学组 中华血液学杂志, 2019,40(5):358-362.

许多国家关于缺铁性贫血治疗的共识,治疗药物主要有口服和静脉铁剂。口服铁剂服用方便,价格低廉,但同时也存在胃肠道不良反应、部分患者口服吸收障碍、纠正贫血速度慢等不利因素。静脉铁剂可更快地升高血红蛋白水平,尤其针对围手术期患者,可更快满足患者需求并减少输血量。但目前临床医师针对静脉铁剂认识不足,受既往铁剂不良反应发生率高等观念限制,导致现有静脉铁剂应用受限。因此本共识主要介绍目前静脉铁剂的优势及不良反

中文标题:

静脉铁剂应用中国专家共识(2019年版)

发布日期:

2019-05-30

简要介绍:

许多国家关于缺铁性贫血治疗的共识,治疗药物主要有口服和静脉铁剂。口服铁剂服用方便,价格低廉,但同时也存在胃肠道不良反应、部分患者口服吸收障碍、纠正贫血速度慢等不利因素。静脉铁剂可更快地升高血红蛋白水平,尤其针对围手术期患者,可更快满足患者需求并减少输血量。但目前临床医师针对静脉铁剂认识不足,受既往铁剂不良反应发生率高等观念限制,导致现有静脉铁剂应用受限。因此本共识主要介绍目前静脉铁剂的优势及不良反应处理,用于指导各科室医师对静脉铁剂的应用。 

拓展指南:铁剂相关指南:

下载附件:

(因为版权问题,不支持下载)

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1179561, encodeId=895711e9561f2, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/8cccaba4e37b47ca8e152a4f732847fb/0d1d2c7e0bd7426b9ecd3318c9f11128.jpg, createdBy=14492036103, createdName=木马🎠, createdTime=Sat Jan 01 18:49:47 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005163, encodeId=4d7610051632a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c115560425, createdName=ms4000000165697337, createdTime=Wed Aug 04 18:32:48 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811877, encodeId=11b28118e70b, content=十分受用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71735400820, createdName=ms7000000334173457, createdTime=Fri Aug 21 17:39:32 CST 2020, time=2020-08-21, status=1, ipAttribution=)]
    2022-01-01 木马🎠

    非常好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1179561, encodeId=895711e9561f2, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/8cccaba4e37b47ca8e152a4f732847fb/0d1d2c7e0bd7426b9ecd3318c9f11128.jpg, createdBy=14492036103, createdName=木马🎠, createdTime=Sat Jan 01 18:49:47 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005163, encodeId=4d7610051632a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c115560425, createdName=ms4000000165697337, createdTime=Wed Aug 04 18:32:48 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811877, encodeId=11b28118e70b, content=十分受用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71735400820, createdName=ms7000000334173457, createdTime=Fri Aug 21 17:39:32 CST 2020, time=2020-08-21, status=1, ipAttribution=)]
    2021-08-04 ms4000000165697337

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1179561, encodeId=895711e9561f2, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/8cccaba4e37b47ca8e152a4f732847fb/0d1d2c7e0bd7426b9ecd3318c9f11128.jpg, createdBy=14492036103, createdName=木马🎠, createdTime=Sat Jan 01 18:49:47 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005163, encodeId=4d7610051632a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c115560425, createdName=ms4000000165697337, createdTime=Wed Aug 04 18:32:48 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811877, encodeId=11b28118e70b, content=十分受用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71735400820, createdName=ms7000000334173457, createdTime=Fri Aug 21 17:39:32 CST 2020, time=2020-08-21, status=1, ipAttribution=)]
    2020-08-21 ms7000000334173457

    十分受用

    0